Kaltofen, Till http://orcid.org/0000-0003-1137-211X
Hagemann, Friederike
Harbeck, Nadia
Wuerstlein, Rachel
Kost, Bernd Peter
Burges, Alexander
Mahner, Sven
Trillsch, Fabian
Funding for this research was provided by:
Ludwig-Maximilians-Universität München
Article History
Received: 7 February 2021
Accepted: 23 August 2021
First Online: 7 September 2021
Declarations
:
: Till Kaltofen reports grants and personal fees from Roche outside the submitted work. Friederike Hagemann declares no conflict of interest. Nadia Harbeck reports grants and personal fees from AstraZeneca, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz and Seattle Genetics outside the submitted work. Rachel Wuerstlein reports grants and personal fees from Agendia, Amgen, Aristo, AstraZeneca, Boeringer Ingelheim, Carl Zeiss, Celgene, Clinsol, Daiichi-Sankyo, Eisai, Genomic Health, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre and Puma Biotechnology outside the submitted work. Bernd Peter Kost declares no conflict of interest. Alexander Burges reports grants and personal fees from AstraZeneca, Roche and Tesaro outside the submitted work. Sven Mahner reports grants and personal fees from AstraZeneca, Clovis, Medac, MSD, PharmaMar, Roche, Sensor Kinesis, Tesaro/GSK and Teva outside the submitted work. Fabian Trillsch reports grants and personal fees from AstraZeneca, Clovis, Medac, PharmaMar, Roche and Tesaro/GSK outside the submitted work.
: Not applicable.
: Not applicable.
: Not applicable.